Oncopeptides’ Pepaxto: US FDA Vexed By Adverse Survival, Failed PFS, Lack Of Dose Optimization

 
• By Sue Sutter
Life ring
Oncopeptides' many post hoc, subgroup analyses cannot save Pepaxto from the adverse survival results in OCEAN, FDA says. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers